ArticleImmunity2016
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection.
Erratum issuedOpen access · bronzeAbstract read
In one paragraph
Article in Immunity, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 100 papers.
0numbers the graph read from it
0cells of the map it votes in
100citing papers in PubMed
12.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
100 citing papers in PubMed, 144 citations in OpenAlex.
- A mycobacterial Sec61 inhibitor disrupts lysosome function by blocking Vacuolar-ATPase biosynthesis.European journal of cell biology · 2026Article
- Therapeutic Efficacy of Indole-3-Carbinol Against SARS-CoV-2-Induced Acute Respiratory Distress Syndrome: A Dual Antiviral and Anti-Inflammatory Approach in a Golden Syrian Hamster Model.Journal of cellular and molecular medicine · 2026Article
- Dissecting the host determinants of orthoflavivirus infection using QIC-seq.PLoS pathogens · 2026Article
- Advancing immunity and disease resistance in chickens through genome editing.Journal of animal science and biotechnology · 2026Review
- SARS-CoV-2 membrane protein biogenesis.bioRxiv : the preprint server for biology · 2026Article
- SEC61: a potential therapeutic target in transplantation.Frontiers in immunology · 2026Review
- The Incoming Influenza Genome Assembles a Host RBP Network that Orchestrates Viral RNA Synthesis.bioRxiv : the preprint server for biology · 2025Article
- COG6 is an essential host factor for influenza A virus infection.Microbiology spectrum · 2025Article
- The glycoprotein quality control factor Malectin promotes coronavirus replication and viral protein biogenesis.bioRxiv : the preprint server for biology · 2025Article
- Comparative IP-MS Reveals HSPA5 and HSPA8 Interacting with Hemagglutinin Protein to Promote the Replication of Influenza A Virus.Pathogens (Basel, Switzerland) · 2025Article
- Metabolism-associated protein network constructing and host-directed anti-influenza drug repurposing.Briefings in bioinformatics · 2025Article
- Overview of host-directed antiviral targets for future research and drug development.Acta pharmaceutica Sinica. B · 2025Review
- Toward Understanding the Mechanism of Client-Selective Small Molecule Inhibitors of the Sec61 Translocon.Journal of molecular recognition : JMR · 2025Review
- Exploring the ER channel protein Sec61: recent advances in pathophysiological significance and novel pharmacological inhibitors.Frontiers in pharmacology · 2025Review
- Review
- Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection.Journal of virology · 2024Article
- Pregnancy enhances antiviral immunity independent of type I IFN but dependent on IL-17-producing γδScience advances · 2024Article
- The endoplasmic reticulum (ER): a crucial cellular hub in flavivirus infection and potential target site for antiviral interventions.Npj viruses · 2024Review
- Functional genomics screens reveal a role for TBC1D24 and SV2B in antibody-dependent enhancement of dengue virus infection.bioRxiv : the preprint server for biology · 2024Article
- Proteomic and genetic analyses of influenza A viruses identify pan-viral host targets.Nature communications · 2023Article
40 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedSachs, David H [corrected to Sachs, David]
Authors and funding
31 authors at 3 institutions in 2 countries.
Nicholas S HeatonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Natasha MoshkinaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Romain FenouilDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Thomas J GardnerDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Sebastian AguirreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Priya S ShahDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158-2140, USA.
Nan ZhaoDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Lara ManganaroDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Judd F HultquistDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158-2140, USA.
Justine NoelDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
David SachsDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Jennifer HamiltonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Paul E LeonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Amit ChawduryTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Shashank TripathiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Camilla MelegariDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Laura CampisiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Rong HaiDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Giorgi MetreveliDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Andrea V GamarnikFundación Instituto Leloir-CONICET, Avenida Patricias Argentinas 435, Buenos Aires 1405, Argentina.
Adolfo García-SastreDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Benjamin GreenbaumTisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Division of Hematology and Oncology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Viviana SimonDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Ana Fernandez-SesmaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Nevan J KroganDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158-2140, USA.
Lubbertus C F MulderDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Harm van BakelDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Domenico TortorellaDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Jack TauntonDepartment of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, CA 94158-2140, USA.
Peter PaleseDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA.
Ivan MarazziDepartment of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA; Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029-6574, USA. Electronic address: ivan.marazzi@mssm.edu.
Icahn School of Medicine at Mount Sinai · USUniversity of California, San Francisco · USConsejo Nacional de Investigaciones Científicas y Técnicas · AR
Funding
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6MProject 3 - Ex vivo immune profiling of dengue viruses and vaccinesU19AI118610 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KASARSKIS, ANDREW · 2015 to 2021
$46.6MVirus CoreU19AI106754 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KROGAN, NEVAN J · 2013 to 2017
$26.0MMolecular Virology and Systems Biology Screening CoreP01AI090935 · NIAID · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI CHANDA, SUMIT K · 2010 to 2014
$20.4MTRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONST32AI007647 · NIAID · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI Domenico Tortorella · 2000 to 2026
$11.5MMicrobial Pathogenesis and Host DefenseT32AI060537 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joanne N. Engel · 2004 to 2026
$6.5MMODULATION OF INNATE AND ADAPTIVE IMMUNITY BY DENGUE VIRUSR01AI073450 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI FERNANDEZ-SESMA, ANA · 2008 to 2017
$3.3MMulti-level analysis of influenza virus polymerase and its role in pathogenesisR01AI113186 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MARAZZI, IVAN, VAN BAKEL, HARM · 2015 to 2019
$3.0MGenomic Determinants of Intrinsic Antiviral Host DefensesR01AI089246 · NIAID · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SIMON, VIVIANA A · 2010 to 2014
$2.1MTransforming Genomics with 5 PB Big Omics Data Engine Cray CS300-AC SupercomputerS10OD018522 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI KOVATCH, PATRICIA · 2014 to 2014
$1.9MImpact of HERV-K expression on HIV-1 life cycleR01GM113886 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI MULDER, LUBBERTUS C · 2014 to 2018
$1.8MGlobal Genetic Interaction Profiling in ProkaryotesR01GM085697 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GROSS, CAROL ANNE · 2008 to 2011
$1.6MNIAID NIH HHS 1R56AI114770-01A1NIAID NIH HHS AI090935NIAID NIH HHS AI101820NIAID NIH HHS F31 AI120648NIAID NIH HHS HHSN272201400008CNIAID NIH HHS P01 AI090935NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI073450NIAID NIH HHS R01 AI089246NIAID NIH HHS R01 AI095175NIAID NIH HHS R01 AI101820NIAID NIH HHS R01 AI113186NIAID NIH HHS R56 AI114770NIAID NIH HHS T32 AI007647NIAID NIH HHS T32 AI060537NIAID NIH HHS U19 AI106754NIAID NIH HHS U19AI106754NIAID NIH HHS U19 AI118610NIGMS NIH HHS R01 GM113886NIH HHS S10 OD018522
Abstract
Viruses are obligate parasites and thus require the machinery of the host cell to replicate. Inhibition of host factors co-opted during active infection is a strategy hosts use to suppress viral replication and a potential pan-antiviral therapy. To define the cellular proteins and processes required for a virus during infection is thus crucial to understanding the mechanisms of virally induced disease. In this report, we generated fully infectious tagged influenza viruses and used infection-based proteomics to identify pivotal arms of cellular signaling required for influenza virus growth and infectivity. Using mathematical modeling and genetic and pharmacologic approaches, we revealed that modulation of Sec61-mediated cotranslational translocation selectively impaired glycoprotein proteostasis of influenza as well as HIV and dengue viruses and led to inhibition of viral growth and infectivity. Thus, by studying virus-human protein-protein interactions in the context of active replication, we have identified targetable host factors for broad-spectrum antiviral therapies.
Indexed as
Models, TheoreticalDengue VirusHIVHost-Parasite InteractionsHumansImmunoprecipitationInfluenza A virusMass SpectrometryProtein FoldingProteomicsVirus Replication
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.